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The Risk-Benefit Balance of Varenicline for
Smoking Cessation
J. Taylor Hays, MD
Recent studies caution us that cellular telephone use may cause malignant brain tumors.1Although there may be an association between the use of cellular telephones and brain
tumors, we all have the sense that this is a purely random event considering the large
number of cellular telephone users. These reports certainly have not dampened our
enthusiastic use of this ubiquitous and now indispensable device. That is because,
although there may be some risks associated with its use, the cellular telephone is also of
great benefit increasing our peace of mind, expanding our productive time, and allowing
us to have contact with emergency services in an instant. The risk-benefit balance favors
the continued widespread use of cellular telephones.
By contrast, there are over 400,000 smoking attributable deaths in United States
annually and it is the leading preventable cause of death. Smoking is the second leading
cause of death worldwide.2,3 Providing effective treatment to help smokers quit is among
the highest public health priorities. The newest non-nicotine drug available for the
treatment of tobacco dependence, varenicline, has recently been placed under scrutiny
because of safety concerns. These concerns have been raised primarily because of a report
from the Institute for Safe Medication Practices (ISMP), a nonprofit consumer watch-dog
organization.4 This report has synthesized voluntary adverse event reports received by the
Food and Drug Administration (FDA) regarding varenicline. The report was generated
because nearly 1000 adverse event reports regarding varenicline were received by the
FDA in the fourth quarter of 2007. This “signal” led to an analysis of over 3000 cases of
serious adverse events reported since the drug was approved. A subset of the over 3000
cases was chosen for further analysis because there were substantial numbers of cases in
multiple definable categories. Among these categories are accidents and injuries, cardiac
arrhythmias, convulsions, and visual disturbances. A total of 78 deaths were reported in
which varenicline was the principal suspect drug. In addition to this report the manufac-
turer of varenicline added a new warning to the label indicating that varenicline has been
associated with neuropsychiatric symptoms including behavior changes, depressive symp-
toms, suicidal ideation, and suicidal behavior.
The ISMP report and recent label changes for varenicline must be considered when
making a decision to prescribe varenicline for the treatment of tobacco dependence, but
for most smokers the risk-benefit balance will still tip in favor of using this effective drug.
The newly published clinical practice guidelines for the treatment of tobacco dependence
indicate that varenicline is perhaps the most effective drug available.5 Clinical trial results
including over 5000 subjects did not demonstrate any significant safety concerns for
varenicline. There are also significant problems with the ISMP report. The report fails to
consider the denominator or number of users of varenicline in United States. It is
estimated that in 2007 alone they were nearly 4 million new users of varenicline. In
addition, in approximately two thirds of all reported serious adverse events other
medications were involved. The most common category of concomitant medication was
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benzodiazepine drugs. Numerous other cases involved the
coadministration of psychoactive drugs including narcotic
analgesics, antidepressants, and antipsychotic medications.
This suggests other competing causes, including psychoac-
tive drug use, for the serious adverse events reported.
In addition there are number of comorbid conditions
that are overrepresented in the population of smokers. These
conditions include cardiovascular disease6 and psychiatric
conditions including depression and suicidality.7 These co-
morbid conditions which are common among smokers also
suggest that there are number of competing causes for the
adverse events reported in association with varenicline use.
For these and other reasons a causal link between varenicline
use and the reported adverse events in the ISMP report as
well as the neuropsychiatric symptoms reported to the FDA
cannot be established.
How should clinicians deal with this information? First,
all clinicians should intervene with every smoker they en-
counter. The intervention should include straightforward ad-
vice to quit smoking, brief behavioral counseling, and the use
of effective pharmacotherapy. Varenicline is but one of many
first-line treatments available. However, there is mounting
evidence that it may be the most effective of available
options. For many who have tried to quit smoking using other
medications, varenicline may be the best option. Patient’s
should be provided information about potential adverse ef-
fects and should be cautioned that if these occur the drug
should be stopped and to contact their prescriber. This is the
kind of advice we provide our patients every day when
beginning new treatments.
Every treatment decision must take into account the
risk-benefit balance. Stopping smoking is the most beneficial
health behavior change a tobacco user can undertake. The
risk of using varenicline in comparison remains small. Until
we have more definitive data, varenicline can be used safely
with appropriate caution and monitoring. Abandoning effec-
tive treatment based on data like this would be akin to throwing
away your cellular phone for fear of inducing a brain tumor.
Until we know more, that decision is a “no-brainer.”
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